Experimental cocktail targets Hard-to-Treat myeloma

NCT ID NCT01562405

Ongoing Disease control Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called sotatercept (ACE-011) combined with standard myeloma drugs lenalidomide or pomalidomide and dexamethasone in 33 patients whose multiple myeloma has returned or stopped responding to treatment. The main goal is to find the safest dose of sotatercept and begin to see if the combination can shrink tumors or slow the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sotatercept (ACE-011) combined with lenalidomide or pomalidomide and dexamethasone
What this could lead to: If this works, it could point toward a new treatment option for multiple myeloma that has stopped responding to other therapies.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and dosing, not yet testing effectiveness. The combination may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Emory University

Atlanta, Georgia, 30322, United States
Massachusetts General Hosptial

Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.